June 14, 2016June 14, 2016

Boehringer Ingelheim, Harvard Scientists Partner to Develop Novel Treatments for IPF, Other Fibrotic Diseases

Boehringer Ingelheim and Harvard Stem Cell Institute’s (HSCI) Harvard Fibrosis Network recently announced a new research partnership to find novel treatments for fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), chronic kidney ... Read more

August 28, 2014November 11, 2015

Pharmaxis Ready to Start Test COPD and NASH Treatment on Humans

COPD, News

The chronic respiratory disorders pharmaceutical specialist Pharmaxis completed the development of its experimental drug, the Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A), which is designed to treat several forms of chronic inflammation ... Read more